eyeforpharma The Marketing Disruption Summit

eyeforpharma2 - 3 October 2019, Philadelphia, USA.
It's 2019 and Marketing is changing. Your customers' expectations have shifted to ‘one-click’. They expect more, they’re used to intuitive consumer interactions, and now they're looking at pharma.

Providing the seamless, personalized experience you've been dreaming about has never seemed closer. But marketers can't do it alone.

The Marketing Disruption Summit attendance is already ahead of expectations, with groups of industry leaders from across Marketing, Strategy, Data and IT already booked to delve deep into specifics with talks, workshops and case studies from top pharma, and equip themselves to be the key changemakers at home.

On current predictions, tickets will sell out this year. Ensure you have a place reserved at the only event where pharma marketing, data & IT change makers redefine customer interaction.

Reach out like never before

With Industry Leading Speakers carefully selected to cover every aspect of the back and front-end customer cycle, and an agenda designed to provide solutions to all the collaborative problems holding back your customer engagement:

Including:

  • Martina Flammer SVP customer value, Boehringer Ingelheim
  • Krishna Cheriath Chief Data Officer BMS
  • Alessandra Almeida Snr Director, Global Head of Master Data Management, Sanofi
  • Ignacio Quiles lara exec director global marketing and commercial ops, Abbvie
  • Ramon Vega head of global pharma marketing IT, Merck
  • Renaud Sermondade Head of insights and analytics, Sanofi

Unite to exceed changing customer demands

Marketers: Understand the technical capabilities within your business, build results-based strategies, and unite teams behind your vision.

Data: Communicate your capabilities and gain vital authority in strategic conversations.

Technology: Show stakeholders what your internal teams can do and inspire new strategies with innovation.

Together: Build cross functional strategies to revolutionize, personalize and redefine customer interaction.

World Pharma News readers can benefit from an exclusive discount, just use the code WPN300 to save $300 when you register here

For further information, please visit:
https://www.eyeforpharma.com/marketingusa/

About eyeforpharma

Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the centre.

Most Popular Now

Intermittent fasting: live 'fast,' live longer?

For many people, the New Year is a time to adopt new habits as a renewed commitment to personal health. Newly enthusiastic fitness buffs pack into gyms and grocery stores...

Pharmacies leave customers hanging when it comes t…

Proper disposal of leftover medication, particularly antibiotics and opioids, can help reduce antibiotic resistance, prevent children from being poisoned and stop the mis...

Scientists find a new use for already known anti-c…

The world scientific community is waging a difficult and prolonged war on cancer. New research in the field of immunogenic cell death can extend the area of drugs applica...

Bayer and Exscientia collaborate to leverage the p…

Bayer and Exscientia Ltd., a UK-based Artificial Intelligence (AI)-driven drug discovery company, have entered into a three-year, multi-target collaboration. The partners...

Researchers determine how a specific protein regul…

Immune checkpoints are surface proteins that cancer cells use to evade immune response. These surface proteins are critical for cancer cell growth and drugs targeting the...

Bristol-Myers Squibb completes divestment of manuf…

Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has completed its previously announced divestment of its oral solid, biologics, and sterile product manufa...

Lynparza approved in the US as a 1st-line maintena…

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that Lynparza (olaparib) has been approved in the US f...

FDA approves first generics of Eliquis

The U.S. Food and Drug Administration has approved two applications for the first generics of Eliquis (apixaban) tablets to reduce the risk of stroke and systemic embolis...

Farxiga granted FDA Priority Review for patients w…

AstraZeneca today announced the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Farxiga (dap...

Aspirin appears to curb colorectal cancer recurren…

The benefits of a daily aspirin may extend beyond heart health to colorectal cancer treatment, say City of Hope researchers who have found aspirin appears to reduce tumor...

Plant-derived SVC112 hits cancer stem cells, leave…

The red, tube-shaped flowers of the firecracker bush (Bouvardia ternifolia), native to Mexico and the American Southwest, attract hummingbirds. The bush also provides the...

Amgen announces global diagnostic collaborations

Amgen (NASDAQ: AMGN) today announced strategic collaborations with leading diagnostic companies Guardant Health, Inc. and QIAGEN N.V. to develop blood- and tissue-based c...